Group 1 - Company Zhaoke Ophthalmology-B (06622) has entered into a distribution and supply agreement with PT Ferron Par Pharmaceuticals for the commercialization of BRIMOCHOL PF in Indonesia [1] - The agreement grants PT Ferron exclusive rights to import, promote, distribute, market, and sell BRIMOCHOL PF in Indonesia, with the company receiving an upfront payment and potential milestone payments based on specific achievements [1] - BRIMOCHOL PF is an experimental preservative-free eye drop designed to correct near vision loss due to aging, with a new drug application accepted by the FDA, and a review deadline set for January 28, 2026 [1][2] Group 2 - PT Ferron Par Pharmaceuticals, a member of the Dexa Group, has been operating since 2001 and is recognized as one of the top 15 largest pharmaceutical companies in Indonesia [3] - The company has received recognition from regulatory bodies such as the UK's Medicines and Healthcare products Regulatory Agency and Portugal's National Authority of Medicines and Health Products, enhancing its credibility [3] - PT Ferron is known for its diverse product portfolio, advanced production capabilities, and strong strategic partnerships, which contribute to its growing market influence and operational excellence [3]